Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Related Parties

Related Parties	3 Months Ended
Mar. 31, 2021
Related Parties
Related Parties	9Related Parties The Company uses Gendreau Consulting, LLC, a consulting firm, for drug development, clinical trial design, and planning, implementation and execution of contracted activities with the clinical research organization. The managing member of the firm is also the Company’s Chief Medical Officer (“CMO”) effective January 1, 2021. The Company will continue to contract the services of the CMO’s spouse through the firm to perform certain activities in connection with its upcoming clinical trial in FM. The Company paid the firm $64,466 and $450 during three months ended March 31, 2021 and 2020, respectively, and had accounts payable of $7,916 and $25,150 to the firm as of March 31, 2021 and December 31, 2020, respectively.

Related Parties

3 Months Ended

Mar. 31, 2021

9Related Parties

The Company uses Gendreau Consulting, LLC, a consulting firm, for drug development, clinical trial design, and planning, implementation and execution of contracted activities with the clinical research organization. The managing member of the firm is also the Company’s Chief Medical Officer (“CMO”) effective January 1, 2021. The Company will continue to contract the services of the CMO’s spouse through the firm to perform certain activities in connection with its upcoming clinical trial in FM. The Company paid the firm $64,466 and $450 during three months ended March 31, 2021 and 2020, respectively, and had accounts payable of $7,916 and $25,150 to the firm as of March 31, 2021 and December 31, 2020, respectively.